SLC5A2 and heart failure: Several placebo-controlled cardiovascular outcome trials (CVOTs) with SGLT2 inhibitors (EMPA-REG OUTCOME with empagliflozin [1], the CANVAS program [2] and CREDENCE [3] with canaglifozin, DECLARE with dapagliflozin [4], VERTIS with Ertugliflozin [5]) demonstrated a reduction in CV events as well as a reduction in hospitalisation for heart failure (HHF) in patients with T2D and atherosclerotic CV disease (ASCVD), multiple CV risk factors, or diabetic nephropathy.